

Claims

1. Use of a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3ε (CD3) and an immunotherapeutic drug selected from the group consisting of thalidomide and an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody, in the manufacture of a medicament for treating multiple myeloma, wherein said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR3L region of SEQ ID NO:20 and a CDR1L and CDR2L region combination selected from the group of
 - i) CDR1L region of SEQ ID NO:23 and CDR2L region of SEQ ID NO:24,
 - ii) CDR1L region of SEQ ID NO:25 and CDR2L region of SEQ ID NO:26, or
 - iii) CDR1L region of SEQ ID NO:27 and CDR2L region of SEQ ID NO:28.
2. The use according to claim 1, characterized in that the immunotherapeutic drug is selected from the group consisting of daratumumab, isatuximab, MOR202, Ab79, Ab19, thalidomide, lenalidomide, pomalidomide, CC-122, CC220, pembrolizumab, pidilizumab, nivolumab, MEDI-0680, PDR001, REGN2810, lambrolizumab, MDX-1106, BGB-108, h409A11, h409A16, h409A17, and atezolizumab.
3. Use of a bispecific antibody in the manufacture of a medicament for treating multiple myeloma, wherein a therapeutically effective amount of the bispecific antibody and an immunotherapeutic drug is to be administered to a patient, wherein
 - a) the bispecific antibody comprises a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3ε (CD3), wherein said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR3L region of SEQ ID NO:20 and a CDR1L and CDR2L region combination selected from the group of
 - i) CDR1L region of SEQ ID NO:23 and CDR2L region of SEQ ID NO:24,
 - ii) CDR1L region of SEQ ID NO:25 and CDR2L region of SEQ ID NO:26, or
 - iii) CDR1L region of SEQ ID NO:27 and CDR2L region of SEQ ID NO:28; and
 - b) the immunotherapeutic drug is selected from the group consisting of thalidomide and an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody.

4. Use of an immunotherapeutic drug in the manufacture of a medicament for treating multiple myeloma, wherein a therapeutically effective amount of the immunotherapeutic drug and a bispecific antibody is to be administered to a patient, wherein
- 5 a) the bispecific antibody comprises a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3ε (CD3), wherein said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR3L region of SEQ ID NO:20 and a CDR1L and CDR2L
 10 region combination selected from the group of
- i) CDR1L region of SEQ ID NO:23 and CDR2L region of SEQ ID NO:24,
 - ii) CDR1L region of SEQ ID NO:25 and CDR2L region of SEQ ID NO:26, or
 - iii) CDR1L region of SEQ ID NO:27 and CDR2L region of SEQ ID NO:28; and
- b) the immunotherapeutic drug is selected from the group consisting of thalidomide and an
 15 immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody.
5. The use according to claim 3 or 4, wherein the immunotherapeutic drug is selected from the group consisting of daratumumab, isatuximab, MOR202, Ab79, Ab19, thalidomide,
 20 lenalidomide, pomalidomide, CC-122, CC-220, pembrolizumab, pidilizumab, nivolumab, MEDI-0680, PDR001, REGN2810, lambrolizumab, MDX-1106, BGB-108, h409A11, h409A16, h409A17, and atezolizumab.
6. A therapeutic combination for achieving multiple myeloma cell lysis in a patient suffering
 25 from multiple myeloma disease, characterized in comprising a therapeutically effective amount of
- a) a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3ε (CD3) and
- 30 b) an immunotherapeutic drug selected from the group consisting of thalidomide and an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody,
- characterized in that said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17
 35 and a VL region comprising a CDR3L region of SEQ ID NO:20 and a CDR1L and CDR2L region combination selected from the group of

- i) CDR1L region of SEQ ID NO:23 and CDR2L region of SEQ ID NO:24,
- ii) CDR1L region of SEQ ID NO:25 and CDR2L region of SEQ ID NO:26, or
- iii) CDR1L region of SEQ ID NO:27 and CDR2L region of SEQ ID NO:28.

7. The therapeutic combination according to claim 6, characterized in that the immunotherapeutic drug is selected from the group consisting of daratumumab, isatuximab, MOR202, Ab79, Ab19, thalidomide, lenalidomide, pomalidomide, CC-122, CC-220, pembrolizumab, pidilizumab, nivolumab, MEDI-0680, PDR001, REGN2810, lambrolizumab, MDX-1106, BGB-108, h409A11, h409A16, h409A17, atezolizumab, avelumab, durvalumab, and MDX-1105.

8. An article of manufacture, characterized in comprising

a) a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3 ϵ (CD3), characterized in that said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR3L region of SEQ ID NO:20 and a CDR1L and CDR2L region combination selected from the group of

- i) CDR1L region of SEQ ID NO:23 and CDR2L region of SEQ ID NO:24,
- ii) CDR1L region of SEQ ID NO:25 and CDR2L region of SEQ ID NO:26, or
- iii) CDR1L region of SEQ ID NO:27 and CDR2L region of SEQ ID NO:28. in a

pharmaceutically acceptable carrier,

b) an immunotherapeutic drug selected from the group consisting of thalidomide and an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody,

c) a pharmaceutically acceptable carrier and instructions for administering said bispecific antibody and said immunotherapeutic drug in combination to a subject in need of a treatment for multiple myeloma.

9. The article of manufacture according to claim 8, characterized in that the immunotherapeutic drug is selected from the group consisting of daratumumab, isatuximab, MOR202, Ab79, Ab19, thalidomide, lenalidomide, pomalidomide, CC-122, CC-220, pembrolizumab, pidilizumab, nivolumab, MEDI-0680, PDR001, REGN2810, lambrolizumab, MDX-1106, BGB-108, h409A11, h409A16, h409A17, atezolizumab, avelumab, durvalumab, and MDX-1105.

10. A method for manufacturing a medicament, characterized in using a therapeutically effective amount of

a) a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3 ϵ

(CD3), characterized in that said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR3L region of SEQ ID NO:20 and a CDR1L and CDR2L region combination selected from the group of

- 5 i) CDR1L region of SEQ ID NO:23 and CDR2L region of SEQ ID NO:24,
- ii) CDR1L region of SEQ ID NO:25 and CDR2L region of SEQ ID NO:26, or
- iii) CDR1L region of SEQ ID NO:27 and CDR2L region of SEQ ID NO:28,
- b) an immunotherapeutic drug selected from the group consisting of thalidomide and an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an
- 10 anti-PD-L1 antibody,
- c) combining said bispecific antibody and said immunotherapeutic drug in a pharmaceutically acceptable carrier.

11. The method for manufacturing a medicament according to claim 10, characterized in that the immunotherapeutic drug is selected from the group consisting of daratumumab, isatuximab,

15 MOR202, Ab79, Ab19, thalidomide, lenalidomide, pomalidomide, CC-122, CC-220, pembrolizumab, pidilizumab, nivolumab, MEDI-0680, PDR001, REGN2810, lambrolizumab, MDX-1106, BGB-108, h409A11, h409A16, h409A17, atezolizumab, avelumab, durvalumab, and MDX-1105.